Wang J, Chen Q, Shan Q, Liang T, Forde P, Zheng L. Clinical development of immuno-oncology therapeutics. Cancer Lett. 2025;617:217616. https://doi.org/10.1016/j.canlet.2025.217616.

Article  CAS  PubMed  Google Scholar 

Linderman SW, DeRidder L, Sanjurjo L, Foote MB, Alonso MJ, Kirtane AR, et al. Enhancing immunotherapy with tumor-responsive nanomaterials. Nat Rev Clin Oncol. 2025;22:262–82. https://doi.org/10.1038/s41571-025-01000-6.

Article  PubMed  Google Scholar 

Ooki A, Shinozaki E, Yamaguchi K. Immunotherapy in colorectal cancer: current and future strategies. J Anus Rectum Colon. 2021;5:11–24. https://doi.org/10.23922/jarc.2020-064.

Article  PubMed  PubMed Central  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40:127–37. https://doi.org/10.1200/jco.21.02229.

Article  CAS  PubMed  Google Scholar 

Wang J, Zhu N, Su X, Yang R. Gut microbiota: a double-edged sword in immune checkpoint blockade immunotherapy against tumors. Cancer Lett. 2024;582:216582. https://doi.org/10.1016/j.canlet.2023.216582.

Article  CAS  PubMed  Google Scholar 

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84. https://doi.org/10.1126/science.aad1329.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest. 2007;117:2197–204. https://doi.org/10.1172/jci32205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967–70. https://doi.org/10.1126/science.1240527.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–6. https://doi.org/10.1126/science.1240537.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602–9. https://doi.org/10.1126/science.abb5920.

Article  CAS  PubMed  Google Scholar 

Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595–602. https://doi.org/10.1126/science.abf3363.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Routy B, Lenehan JG, Miller WH Jr, Jamal R, Messaoudene M, Daisley BA, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med. 2023;29:2121–32. https://doi.org/10.1038/s41591-023-02453-x.

Article  CAS  PubMed  Google Scholar 

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24:1804–8. https://doi.org/10.1038/s41591-018-0238-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Redenti A, Im J, Redenti B, Li F, Rouanne M, Sheng Z, et al. Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature. 2024;635:453–61. https://doi.org/10.1038/s41586-024-08033-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med. 2022;28:2344–52. https://doi.org/10.1038/s41591-022-01965-2.

Article  CAS  PubMed  Google Scholar 

Yang J, Wei H, Zhou Y, Szeto CH, Li C, Lin Y, et al. High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites. Gastroenterology. 2022;162:135–.e132. https://doi.org/10.1053/j.gastro.2021.08.041.

Article  CAS  PubMed  Google Scholar 

Bai X, Wei H, Liu W, Coker OO, Gou H, Liu C, et al. Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites. Gut. 2022;71:2439–50. https://doi.org/10.1136/gutjnl-2021-325021.

Article  CAS  PubMed  Google Scholar 

Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14:195–206. https://doi.org/10.1016/j.chom.2013.07.012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung L, Thiele Orberg E, Geis AL, Chan JL, Fu K, DeStefano Shields CE, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe. 2018;23:203–214.e205. https://doi.org/10.1016/j.chom.2018.01.007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma M, Jiang W, Zhou R. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity. 2024;57:752–71. https://doi.org/10.1016/j.immuni.2024.03.002.

Article  CAS  PubMed  Google Scholar 

Man SM, Jenkins BJ. Context-dependent functions of pattern recognition receptors in cancer. Nat Rev Cancer. 2022;22:397–413. https://doi.org/10.1038/s41568-022-00462-5.

Article  CAS  PubMed  Google Scholar 

Hamada T, Zhang X, Mima K, Bullman S, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol Res. 2018;6:1327–36. https://doi.org/10.1158/2326-6066.Cir-18-0174.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun C-H, Li B-B, Wang B, Zhao J, Zhang X-Y, Li T-T, et al. The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management. Chronic Dis Transl Med. 2019;5:178–87. https://doi.org/10.1016/j.cdtm.2019.09.001.

Article  PubMed  PubMed Central  Google Scholar 

Despins CA, Brown SD, Robinson AV, Mungall AJ, Allen-Vercoe E, Holt RA. Modulation of the host cell transcriptome and epigenome by Fusobacterium nucleatum. mBio. 2021;12:e0206221. https://doi.org/10.1128/mBio.02062-21.

Article  PubMed  Google Scholar 

Udayasuryan B, Zhou Z, Ahmad RN, Sobol P, Deng C, Nguyen TTD, et al. Fusobacterium nucleatum infection modulates the transcriptome and epigenome of HCT116 colorectal cancer cells in an oxygen-dependent manner. Commun Biol. 2024;7:551 https://doi.org/10.1038/s42003-024-06201-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Fang Y, Liang W, Wong CC, Qin H, Gao Y, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell. 2024;42:1729–1746.e1728. https://doi.org/10.1016/j.ccell.2024.08.019.

Article  CAS  PubMed